SingleBioregulators

Cerluten 20mg

An oral animal-derived central nervous system peptide complex investigated in bioregulator models for neural integrity and cognitive health.

Mechanism

Postulated to act via tissue-specific organotropic signaling where low-molecular-weight brain-derived peptides modulate gene expression, support neuronal metabolism, and mitigate cellular excitotoxicity.

Dosing

Standard investigational protocols typically document an initial administration of 20 mg (one capsule) daily.

Reconstitution

Cerluten is an encapsulated solid intended for oral research and requires no reconstitution with bacteriostatic water.

Storage

Store sealed at controlled room temperature in a dry location shielded from heat and direct light.

Mix & measure Cerluten 20mg

Pre-filled with this protocol's recommended BAC water and documented starting dose — edit any field to run your own numbers.

Mix & measure Cerluten 20mg

Vial strength → BAC water → target dose

Vial strength

BAC water

Target dose

Concentration—

Draw volume—

On the syringe—

Total doses in vial: —

100u80u60u40u20u0

U-100 syringe: 100 units = 1 mL

Reconstitution math only — not dosing advice. U-100 syringe: 100 units = 1 mL. Advanced calculator →

Dosing Chart

Phase / Day(s)	Dose & Frequency	Volume (U-100 units / mL)
Initiation (Days 1–10)	20 mg (1 capsule) daily	N/A (Oral)
Standard Course (Days 11–30)	20–40 mg (1–2 capsules) daily	N/A (Oral)
Maintenance Pulse	Repeat 10–30 day course 2–3 times/year	N/A (Oral)

Reconstitution Steps

1
Verify the integrity of the packaging and confirm the labeled milligram strength per capsule.
2
Bypass liquid reconstitution procedures, as this preparation is provided as a pre-measured solid oral capsule.
3
Ensure standard oral delivery equipment (such as clean laboratory water for swallowing) is prepared.
4
Administer the capsule intact without crushing, opening, or dissolving the outer shell.
5
Reseal the original container immediately to prevent exposure to ambient moisture or degradation.

Supplies Needed

Peptide Vial

Encapsulated oral bioregulator supply containing 20 mg of brain tissue peptide complex

Insulin Syringes (U-100)

Not applicable for this oral formulation

Bacteriostatic Water

Not applicable for solid capsule administration

Alcohol Swabs

Not required for enteral laboratory administration

Why researchers study it

Brain & cognitive health models

Neuronal recovery and ischemic cascades

Tissue-specific bioregulator peptide mechanisms

Enteral peptide absorption and CNS signaling

These describe what is being studied, not proven benefits, approved uses, or promised results.

Overview

Cerluten (designated Cytomax A-5) represents a proprietary biological extract derived from animal central nervous system tissue, specifically formulated as an oral peptide bioregulator. Developed within the conceptual framework of Russian organotropic peptide research, it is investigated for its potential role in modulating cellular homeostasis, protein synthesis, and metabolic resilience within neuronal tissue. While marketed and utilized internationally as a dietary supplement or parapharmaceutical, scientific investigations into natural brain bioregulators frequently intersect with findings from defined pharmaceutical counterparts, such as Cortexin and the synthetic peptide Cortagen. Researchers frequently assess Cerluten to explore whether short-chain, tissue-specific peptide mixtures exert comparable cellular-signaling or neuroprotective influences when administered via enteral pathways. Because Cerluten is supplied exclusively as a solid oral preparation, standard peptide laboratory techniques involving reconstitution, liquid measurement, and parenteral injection do not apply. The literature primarily documents its use across structured multi-week pulses rather than persistent chronic regimens.

References

1.Khavinson, Neuroendocrinology Letters, 2002 — Peptides and Ageing
2.Fedin et al., Zh Nevrol Psikhiatr im S.S. Korsakova, 2021 — Multimodal therapeutic strategies in cerebrovascular disease
3.Shavlovskaya, Zh Nevrol Psikhiatr im S.S. Korsakova, 2016 — Clinical efficacy of neuropeptides in cerebrovascular pathology
4.Khavinson et al., Advances in Gerontology, 2013 — Peptide bioregulators: a new class of geroprotectors (clinical studies results)